Revenue

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Dupixent Revenue	14.93B	13.07B	Log In	Log In	Log In	Upgrade
Total Neurology & Immunology Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Rare Diseases Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Oncology Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Rare Blood Disorders Revenue	-	-	Log In	Log In	Log In	Upgrade
Pharma Revenue	34.81B	32.78B	Log In	Log In	Log In	Upgrade
Total Vaccine Revenue	8.07B	8.30B	Log In	Log In	Log In	Upgrade
BioPharma Revenue	42.89B	41.08B	Log In	Log In	Log In	Upgrade
Specialty Care Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Core Assets Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Non-Core Assets Revenue	-	-	Log In	Log In	Log In	Upgrade
Industrial Revenue	-	-	Log In	Log In	Log In	Upgrade
Total Pharmaceutical Revenue	-	-	Log In	Log In	Log In	Upgrade
Opella Consumer Healthcare Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Other)	-11.88B	-9.87B	Log In	Log In	Log In	Upgrade
Revenue (Total)	45.93B	44.29B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
United States Revenue	21.52B	19.99B	Log In	Log In	Log In	Upgrade
Europe Revenue	9.17B	9.03B	Log In	Log In	Log In	Upgrade
Rest of World Revenue	12.20B	12.07B	Log In	Log In	Log In	Upgrade
Revenue (Other)	3.04B	3.21B	Log In	Log In	Log In	Upgrade
Revenue (Total)	45.93B	44.29B	Log In	Log In	Log In	Upgrade

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Biopharma Operating Income	11.82B	11.29B	Log In	Log In	Log In	Upgrade
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income	-	-	Log In	Log In	Log In	Upgrade
Other (Post-2022 Reporting) Operating Income	63.00M	58.00M	Log In	Log In	Log In	Upgrade
Pharmaceutical Operating Income	-	-	Log In	Log In	Log In	Upgrade
Vaccine Operating Income	-	-	Log In	Log In	Log In	Upgrade
Consumer Healthcare Operating Income	-	-	Log In	Log In	Log In	Upgrade
Other Operating Income	-	-	Log In	Log In	Log In	Upgrade
Operating Income (Other)	-3.32B	-4.09B	Log In	Log In	Log In	Upgrade
Operating Income (Total)	8.57B	7.25B	Log In	Log In	Log In	Upgrade

Updated Oct 24, 2025. Data Source: Fiscal.ai.